Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DCP0I8
|
|||
| Drug Name |
ACU193
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1] | |
| Company |
Acumen Pharmaceuticals Charlottesville, VA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04931459) A Phase 1 Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease. U.S.National Institutes of Health. | |||
| REF 2 | ACU193, a Monoclonal Antibody that Selectively Binds Soluble A? Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan. J Prev Alzheimers Dis. 2023;10(1):19-24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.